Trial reportRadiology. Imaging cancer2023
Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI.
Registry-linked trialOpen access · diamondAbstract readClinical Trial
In one paragraph
Trial report in Radiology. Imaging cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01542879 (Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.), which is not on this map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Activatable MRI nanoprobes for tumor and immune microenvironment imaging: biological mechanisms and translational implications.Materials today. Bio · 2026Review
- A Review on Novel Applications of Nanoparticles in Pediatric Oncology.Oncology research · 2025Review
- Nanomedicine and clinical diagnostics part I: applications in conventional imaging (MRI, X-ray/CT, and ultrasound).Nanomedicine (London, England) · 2025Review
- Cardiovascular Information and Health Engineering Medicine.Research (Washington, D.C.) · 2025Review
- Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.National science review · 2024Review
- Fibrinogen-to-albumin ratios are related to mortality in patients with secondary malignant neoplasm of bone and bone marrow.Heliyon · 2023Article
- Ferumoxytol: Another Exciting Addition to the Growing Field of Bone Marrow Imaging.Radiology. Imaging cancer · 2023Article
- Nanoparticle Contrast Agents for Photon-Counting Computed Tomography: Recent Developments and Future Opportunities.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Ali RashidiFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.ORCID 0000-0001-5820-6990
Lucia BarattoFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.ORCID 0000-0002-1646-4876
Ashok Joseph TheruvathFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.ORCID 0000-0003-0764-6800
Elton Benjamin GreeneFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.
Praveen JayapalFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.
K Elizabeth HawkFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.
Rong LuFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.
Jayne SeekinsFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.
Sheri L SpuntFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.ORCID 0000-0002-1669-2676
Allison PribnowFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.ORCID 0000-0001-7069-3402
Heike E Daldrup-LinkFrom the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children's Hospital, Stanford University School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654; and Quantitative Sciences Unit (R.L.) and Department of Pediatrics, Division of Hematology/Oncology (S.L.S., A.P., H.E.D.L.), Stanford University School of Medicine, Stanford, Calif.ORCID 0000-0002-4929-819X
Lucile Packard Children's Hospital · US
Funding
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4MStanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0MMonitoring of Stem Cell Engraftment in Arthritic Joints with MR ImagingR01AR054458 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DALDRUP-LINK, HEIKE ELIZABETH · 2008 to 2021
$6.7MAdvanced Imaging Tools to Assess Cancer Therapeutics in Pediatric PatientsR01CA269231 · NCI · STANFORD UNIVERSITY · PI Heike Elizabeth Daldrup-Link · 2022 to 2026
$3.5MTheranostics for Pediatric Brain CancerR01HD103638 · NICHD · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2021 to 2025
$3.3MCo-Clinical Research Resource for Imaging Tumor Associated MacrophagesU24CA264298 · NCI · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH, GATIDIS, SERGIOS · 2021 to 2025
$3.2MCellular Senescence Network: New Imaging Tools for Arthritis ImagingUG3CA268112 · NCI · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2021 to 2022
$1.1MImaging Chemotherapy-Induced Brain Damage in Pediatric Cancer SurvivorsR21HD101129 · NICHD · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2020 to 2021
$434kInstant Stem Cell Labeling with a new Microfluidic DeviceR21AR075863 · NIAMS · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2019 to 2020
$379kNCATS NIH HHS UL1 TR003142NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA269231NCI NIH HHS U24 CA264298NCI NIH HHS UG3 CA268112NIAMS NIH HHS R01 AR054458NIAMS NIH HHS R21 AR075863NICHD NIH HHS R01 HD103638NICHD NIH HHS R21 HD101129
Abstract
Purpose To evaluate if ferumoxytol can improve the detection of bone marrow metastases at diffusion-weighted (DW) MRI in pediatric and young adult patients with cancer. Materials and Methods In this secondary analysis of a prospective institutional review board-approved study (ClinicalTrials.gov identifier NCT01542879), 26 children and young adults (age range: 2-25 years; 18 males) underwent unenhanced or ferumoxytol-enhanced whole-body DW MRI between 2015 and 2020. Two reviewers determined the presence of bone marrow metastases using a Likert scale. One additional reviewer measured signal-to-noise ratios (SNRs) and tumor-to-bone marrow contrast. Fluorine 18 (
Indexed as
Bone Marrow NeoplasmsBone NeoplasmsAdolescentAdultChildChild, PreschoolFerrosoferric OxideHumansMagnetic Resonance ImagingMaleProspective StudiesYoung AdultFerrosoferric OxideBone MarrowCancer ImagingComparative StudiesFerumoxytolMolecular Imaging–CancerMolecular Imaging–NanoparticlesMR–Diffusion Weighted ImagingMR ImagingPediatricsSkeletal-AppendicularSkeletal-AxialUSPIO
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01542879ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.